Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

BACKGROUND: We report updated data for avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma from the third interim analysis of the phase III JAVELIN Renal 101 trial. PATIENTS AND METHODS: Progression-free survival (PFS), objective response rate (ORR), and duration o...

Descripción completa

Detalles Bibliográficos
Autores principales: Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265611/
https://www.ncbi.nlm.nih.gov/pubmed/37104931
http://dx.doi.org/10.1016/j.esmoop.2023.101210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265611/
https://www.ncbi.nlm.nih.gov/pubmed/37104931
http://dx.doi.org/10.1016/j.esmoop.2023.101210

Ejemplares similares